Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

被引：17

作者：

Kim, Tae Min ^{[1
]}

Taszner, Michal ^{[2
]}

Cho, Seok-Goo ^{[3
]}

Novelli, Silvana ^{[4
]}

Le Gouill, Steven ^{[5
]}

Poon, Michelle Limei ^{[6
]}

Villasboas, Jose C. ^{[7
]}

Champion, Rebecca ^{[8
]}

Bachy, Emmanuel ^{[9
,10
]}

Guidez, Stephanie ^{[11
]}

Alonso, Aranzazu Alonso ^{[12
]}

Jagadeesh, Deepa ^{[13
]}

Merli, Michele ^{[14
]}

Tucker, David ^{[15
]}

Cai, Jingxian ^{[16
]}

De Oliveira, Carolina Leite ^{[16
]}

Zhu, Min ^{[16
]}

Chaudhry, Aafia ^{[16
]}

Mohamed, Hesham ^{[16
]}

Ambati, Srikanth R. ^{[16
]}

Luminari, Stefano ^{[17
]}

机构：

[1] Seoul Natl Univ Hosp, Seoul, South Korea

[2] Uniwersyteckie Ctr Kliniczne Klin Hematol & Trans, Gdansk, Poland

[3] Catholic Univ Korea, Seoul St Marys Hosp Hematol, Seoul, South Korea

[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[5] Hosp Grp Inst Curie, Paris, France

[6] Hematol Oncol Natl Univ Hosp, Singapore, Singapore

[7] Mayo Clin, Rochester, NY USA

[8] Norton Canc Inst, Louisville, KY USA

[9] Hosp Civils Lyon, Lyon, France

[10] Univ Claude Bernard Lyon 1, Lyon, France

[11] Ctr Hosp Univ CHU Poitiers, Poitiers, France

[12] Hosp Univ Quiron Salud Madrid, Madrid, Spain

[13] Cleveland Clin, Main Campus, Cleveland, OH 44106 USA

[14] Osped Circolo & Fdn Macchi, Hematol, Varese, Italy

[15] Royal Cornwall Hosp, Truro, Cornwall, England

[16] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[17] Azienda Unita Sanitaria Locale IRCCS, Div Hematol, Reggio Emilia, Italy

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158404

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2280 / 2282

页数：3

共 50 条

[1] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
Chong, Geoffrey
Taszner, Michal
Novelli, Silvana
Cho, Seok-Goo
Villasboas, Jose C.
Ubieto, Ana Jimenez
Tessoulin, Benoit
Poon, Michelle
Tucker, David
Walewski, Jan
Song, Yuqin
Bachy, Emmanuel
Guidez, Stephanie
Alonso, Aranzazu
Jagadeesh, Deepa
Luminari, Stefano
Mayer, Laura Magnano
Iskierka-Jazdzewska, Elzbieta
Tani, Monica
Cai, Jingxian
Uppala, Amulya
Shariff, Saleem
Brouwer-Visser, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Kim, Tae Min
CANCER RESEARCH, 2024, 84 (07)
[2] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog
Kim, Tae Min
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle Limei
Prince, H. Miles
Oh, Sung Yong
Lim, Francesca
Carpio, Cecilia
Tran-Der Tan
Ayyappan, Sabarish
Gutierrez, Antonio
Li, Jingjin
Ufkin, Melanie
Zhu, Min
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Walewski, Jan
BLOOD, 2022, 140 : 1070 - 1071
[3] Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
Villasboas, Jose. C.
Kim, Tae Min
Taszner, Michal
Novelli, Silvana
Cho, Seok-Goo
Merli, Michele
Ubieto, Ana Jimenez
Tessoulin, Benoit
Poon, Michelle
Walewski, Jan
Yi, Shuhua
Song, Yuqin
Chong, Geoffrey
Luminari, Stefano
Bachy, Emmanuel
Guidez, Stephanie
Alonso, Aranzazu
Jagadeesh, Deepa
Zhang, Wei
Magnano, Laura
Iskierka-Jazdzewska, Elzbieta
Tani, Monica
Cai, Jessica
Uppala, Amulya
Shariff, Saleem
Chi, Lei
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Tucker, David
BLOOD, 2023, 142
[4] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish
Kim, Won Seog
Kim, Tae Min
Walewski, Jan
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle
Oh, Sung Yong
Lim, Francesca Lorraine Wei Inng
Carpio, Cecilia
Tan, Tran-Der
Gutierrez, Antonio
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Li, Jingjin
Ufkin, Melanie
Shariff, Saleem
Chi, Lei
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Prince, H. Miles
BLOOD, 2023, 142
[5] Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies
Zhu, Min
Conrado, Daniela
Srinivasan, Kamal
Brouwer-Visser, Jurriaan
Yan, Hong
Mohamed, Hesham
Chaudhry, Aafia
Ambati, Srikanth
Harnisch, Lutz
Davis, John D.
BLOOD, 2023, 142
[6] Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.
Villasboas, Jose Caetano
Mayer, Laura Magnano
Tessoulin, Benoit
Cho, Seok-Goo
Taszner, Michal
Novelli, Silvana
Luminari, Stefano
Merli, Michele
Ubieto, Ana Jimenez
Poon, Michelle
Tucker, David
Walewski, Jan Andrzej
Ivanescu, Cristina
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Harnett, James
Kamat, Siddhesh
Kim, Tae Min
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
Borchmann, Peter
Morschhauser, Franck
Dahiya, Saurabh
Palomba, M. Lia
Garcia-Sancho, Alejandro Martin
Reguera Ortega, Juan Luis
Kuruvilla, John
Jaeger, Ulrich
Cartron, Guillaume
Izutsu, Koji
Dreyling, Martin
Kahl, Brad
Ghesquieres, Herve
Ardeshna, Kirit
Goto, Hideki
Barbui, Anna Maria
Abramson, Jeremy S.
Fleury, Isabelle
Mielke, Stephan
Farazi, Thalia
Fasan, Omotayo
Lymp, James
Vedal, Min
Nishii, Rina
Avilion, Ariel
Papuga, Jessica
Nastoupil, Loretta J.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143
[8] Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Kim, Won Seog
Kim, Tae Min
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Li Mei
Prince, H. Miles
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Oh, Sung Yong
Lim, Francesca
Carpio, Cecilia
Tan, Tran-Der
Ayyappan, Sabarish
Gutierrez, Antonio
Cai, Jingxian
Ufkin, Melanie
Sharif, Saleem
Brouwer-Visse, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Walewski, Jan
NATURE CANCER, 2025, 6 (03) : 528 - 539
[9] Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Pagel, John
Morschhauser, Franck
Herve, Tilly
Chaidos, Aristeidis
Phillips, Tycel
Ribrag, Vincent
Campbell, Phillip
Fruchart, Christophe
Jurczak, Wojciech
McKay, Pamela
Opat, Stephen
Radford, John
McDonald, Alice
Howell, Haley
Newberry, Kate
Woodruff, Mark
Clawson, Alicia
Larus, John
Blakemore, Stephen
Miao, Harry
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S278 - S279
[10] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392

← 1 2 3 4 5 →